Table 2.
Prognostic factors | OS | PFS | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95 % CI | p value | Hazard ratio | 95 % CI | p value | |
LMR: high versus low | 0.528 | 0.129–0.849 | 0.008 | 0.541 | 0.136–0.894 | 0.002 |
HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA | 0.404 | 0.025–0.647 | 0.001 | 0.529 | 0.151–0.826 | 0.001 |
Age : ≤46 versus >46 | 0.452 | 0.121–0.837 | 0.014 | 0.412 | 0.087–1.030 | 0.040 |
FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA | 0.197 | 0.018–0.416 | 0.034 | 0.484 | 0.0134–0.839 | 0.024 |
pathological type: SCC versus ADC versus ASC versus UDC | 0.418 | 0.168–0.827 | 0.031 | 0.478 | 0.174–0.930 | 0.043 |
Lymph node status classification: positive lymph node versus negative lymph node | 3.586 | 0.876–5.439 | 0.043 | 2.542 | 1.047–4.283 | 0.045 |
Treatment modality: IC + RT versus CCRT versus IC + CCRT | 0.530 | 0.129–0.934 | 0.039 | 2.164 | 1.687–4.017 | 0.102 |
ALC: high versus low | 0.571 | 0.292–0.843 | 0.002 | 0.513 | 0.385–0.738 | 0.008 |
AMC: high versus low | 2.418 | 1.215–4.738 | 0.931 | 0.714 | 0.306–1.136 | 0.035 |
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma, UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count